A phase 1 dose-escalation study to examine the safety and tolerability of LY2603618 administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

被引：0
|
作者：
Weiss, G. [1 ]
Donehower, R. [2 ]
Westin, E. [3 ]
Bence, A. [4 ]
Hynes, S. [5 ]
Hurt, K. [6 ]
机构：
[1] TGEN Clin Res, Canc & Cell Biol Div, Scottsdale, AZ USA
[2] Johns Hopkins Univ, Med Ctr, Baltimore, MD 21218 USA
[3] Eli Lilly & Co, Med Oncol Exploratory Preclin, Indianapolis, IN 46285 USA
[4] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[5] Eli Lilly & Co, Program Phase, Indianapolis, IN 46285 USA
[6] Eli Lilly & Co, Clin Oncol, Indianapolis, IN 46285 USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72223-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：165 / 165
页数：1
相关论文
共 50 条
  • [41] A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors
    Kim, Gun Min
    Reid, Tony
    Shin, Sang Joon
    Rha, Sun Young
    Ahn, Joong Bae
    Lee, Sung Sil
    Chung, Hyun Cheol
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 773 - 781
  • [42] A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors
    Gun Min Kim
    Tony Reid
    Sang Joon Shin
    Sun Young Rha
    Joong Bae Ahn
    Sung Sil Lee
    Hyun Cheol Chung
    Investigational New Drugs, 2017, 35 : 773 - 781
  • [43] Temozolomide (TMZ) for progressive primitive brain tumors:: safety at 75 mg/m2 a day for 21 days every 28:: A GICNO (Italian Neuro-Oncology Group) study.
    Brande, AA
    Cavallo, G
    Tosoni, A
    Ermani, M
    Franceschi, E
    Scopece, L
    Ghimenton, C
    Blatt, V
    Nicolardi, L
    Crinò, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 124S - 124S
  • [44] A PHASE 1/2, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF BMN 110 IN SUBJECTS WITH MUCOPOLYSACCHARIDOSIS IVA (MORQUIO SYNDROME)
    Hendriksz, C.
    Vellodi, A.
    Jones, S.
    Capponi, M.
    Decker, C.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2010, 33 : S143 - S143
  • [45] Results of a phase 1, open-label, dose-escalation study evaluating the safety and tolerability of EZN-3042, a survivin mRNA antagonist, administered with or without docetaxel in adult patients with advanced solid tumors or lymphoma
    Tolcher, Anthony W.
    Patnaik, Amita
    Papadopoulos, Kyriakos P.
    Agnew, James
    Lokiec, Francois M.
    Rezai, Keyvan
    Kalambakas, Stacey
    Buchbinder, Aby
    CANCER RESEARCH, 2011, 71
  • [46] Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
    Reid, Tony
    Oronsky, Bryan
    Scicinski, Jan
    Scribner, Curt L.
    Knox, Susan J.
    Ning, Shoucheng
    Peehl, Donna M.
    Korn, Ron
    Stirn, Meaghan
    Carter, Corey A.
    Oronsky, Arnold
    Taylor, Michael J.
    Fitch, William L.
    Cabrales, Pedro
    Kim, Michelle M.
    Burris, Howard A.
    Lao, Christopher D.
    Abrouk, Nacer E. D.
    Fanger, Gary R.
    Infante, Jeffrey R.
    LANCET ONCOLOGY, 2015, 16 (09): : 1133 - 1142
  • [47] Long Term Outcomes of a Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome)
    Hendriksz, Christian
    Vellodi, Ashok
    Jones, Simon
    Takkele, Hiwot
    Lee, S.
    Chesler, Sarah
    Decker, Celeste
    MOLECULAR GENETICS AND METABOLISM, 2012, 105 (02) : S35 - S35
  • [48] Phase 1/2a, open-label, dose-escalation and safety study of APC-100 in men with advanced prostate cancer.
    Kyriakopoulos, Christos
    Heath, Elisabeth I.
    Eickhoff, Jens C.
    Kolesar, Jill
    Yayehyirad, Mulusew
    Moll, Thomas
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [49] A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours
    Christophe Le Tourneau
    Jean-Pierre Delord
    Nuria Kotecki
    Edith Borcoman
    Carlos Gomez-Roca
    Ségolène Hescot
    Christiane Jungels
    Anne Vincent-Salomon
    Vincent Cockenpot
    Lauriane Eberst
    Audrey Molé
    Wael Jdey
    Françoise Bono
    Véronique Trochon-Joseph
    Hélène Toussaint
    Christelle Zandanel
    Olga Adamiec
    Olivier de Beaumont
    Philippe Alexandre Cassier
    British Journal of Cancer, 2020, 123 : 1481 - 1489
  • [50] A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies.
    Salgia, Ravi
    Hong, David
    Sherman, Steven I.
    Ng, Chann
    Frye, John
    Janish, Linda
    Ratain, Mark
    Kurzrock, Razelle
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3385S - 3385S
12345